Are we repeating the statin playbook with lipoprotein(a)?
In the late 1970s, a Japanese biochemist named Akira Endo discovered a compound from fungus that inhibited HMG-CoA reductase, the enzyme responsible for making cholesterol. It was an academic curiosity at the time. No one knew if lowering cholesterol would prevent heart attacks—it just lowered a number on a lab slip.
That compound eventually became lovastatin, and in 1987, Merck brought it to market with no proof of improved outcomes—only a …
Are we repeating the statin playbook with lipoprotein(a)?















![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)




![True metabolic healing requires more than just prescribing expensive peptides [PODCAST]](https://kevinmd.com/wp-content/uploads/bac3c442-618d-4603-944d-2f94e78ad46b-190x100.jpeg)

